メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
Keio University ホーム
ヘルプ＆FAQ
!!Link opens in a new tab
English
日本語
Keio Universityでコンテンツを検索
ホーム
プロファイル
研究部門
研究成果
医学部臨床教室
学部
医学部
概要
フィンガープリント
ネットワーク
プロファイル
(282)
研究成果
(18033)
フィンガープリント
医学部臨床教室が活動している研究トピックを掘り下げます。これらのトピックラベルは、この組織のメンバーの研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Neoplasm
100%
Surgery
60%
Disease
57%
Computer Assisted Tomography
44%
Recurrent Disease
43%
Overall Survival
41%
Malignant Neoplasm
40%
Symptom
31%
Retrospective Study
30%
Esophageal Cancer
27%
Magnetic Resonance Imaging
27%
Hazard Ratio
27%
COVID-19
26%
Odds Ratio
25%
Percutaneous Aortic Valve Replacement
24%
Adverse Event
24%
Percutaneous Coronary Intervention
22%
Survival Rate
22%
Dry Eye
22%
Bleeding
21%
Lung Cancer
21%
Quality of Life
21%
Metastatic Carcinoma
21%
Systematic Review
21%
Esophagectomy
20%
Prognostic Factor
20%
Injury
19%
Endometrial Cancer
18%
Biological Marker
18%
Clear Cell Renal Cell Carcinoma
18%
Heart Failure
18%
Observational Study
17%
Prostate Cancer
17%
Hepatocellular Carcinoma
17%
Cohort Analysis
17%
Surgeon
17%
Clinical Trial
17%
Infection
17%
Transitional Cell Carcinoma
17%
Multivariate Analysis
17%
Meta-Analysis
16%
Prevalence
16%
Retrospective Cohort Study
16%
Diagnosis
16%
Stomach Cancer
16%
Apoplexy
15%
Colorectal Cancer
15%
Lymph Node Metastasis
15%
Randomized Controlled Trial
15%
Rheumatoid Arthritis
15%
Body Mass Index
15%
Spinal Cord Injury
15%
Hepatectomy
15%
Postoperative Complication
14%
Non Small Cell Lung Cancer
14%
Cardiovascular System
14%
Radiation Therapy
14%
Ulcerative Colitis
13%
Recurrence Free Survival
13%
Ossification
13%
Adenocarcinoma
13%
Pediatrics
13%
Cervical Cancer
12%
Cell Transplantation
12%
Atrial Fibrillation
12%
Elderly Patient
12%
Drug Therapy
12%
Liver Transplantation
12%
Logistic Regression Analysis
12%
Cancer Surgery
12%
Esophageal Squamous Cell Carcinoma
12%
Induced Pluripotent Stem Cell
12%
Combination Therapy
12%
Cancer
12%
Progression Free Survival
12%
Medicine
11%
Posterior Longitudinal Ligament
11%
Retroperitoneal Lymph Node Dissection
11%
Adolescent Idiopathic Scoliosis
11%
Neoadjuvant Chemotherapy
11%
Visual Acuity
11%
Cross Sectional Study
11%
In Vitro
11%
Stem Cell
11%
Breast Cancer
11%
Ovarian Cancer
10%
Diabetes
10%
Biopsy
10%
Hospital Mortality
10%
Surgical Technique
10%
Clinical Feature
10%
Chemoradiotherapy
10%
Cardiac Muscle Cell
10%
Cancer Cell
10%
Cisplatin
9%
Lymph Node
9%
Allogeneic Hematopoietic Stem Cell Transplantation
9%
Pelvis
9%
Transplantation
9%
Pulmonary Hypertension
9%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
55%
Neoplasm
46%
Mouse
42%
Malignant Neoplasm
37%
Chemotherapy
30%
Adverse Event
28%
Overall Survival
26%
Recurrent Disease
24%
Rheumatoid Arthritis
24%
Remission
22%
Symptom
21%
Cohort Study
20%
Heart Failure
20%
Biological Marker
16%
Clinical Trial
16%
Antipsychotic
16%
Combination Therapy
15%
Infection
15%
Retrospective Study
15%
Renal Cell Carcinoma
15%
Cisplatin
15%
Randomized Controlled Trial
14%
Pharmacokinetics
14%
Inflammation
13%
Observational Study
13%
Progression Free Survival
13%
Receptor
13%
Survival Rate
13%
Prostate Cancer
13%
Ulcerative Colitis
12%
Prevalence
12%
Lung Cancer
12%
Coronavirinae
12%
Cardiovascular Disease
11%
Stomach Cancer
11%
Atrial Fibrillation
11%
Dry Eye
11%
Cytokine
11%
Colorectal Cancer
10%
Typical Antipsychotic
10%
Monotherapy
10%
Non Small Cell Lung Cancer
10%
Liver Cell Carcinoma
10%
Esophagus Cancer
10%
Diseases
9%
Mouse Model
9%
Injury
9%
Non Insulin Dependent Diabetes Mellitus
9%
Chronic Kidney Failure
9%
Placebo
9%
Syndrome
9%
Transitional Cell Carcinoma
8%
Tumor Necrosis Factor
8%
Chemoradiation Therapy
8%
Pulmonary Hypertension
8%
Diabetes Mellitus
8%
Epidermal Growth Factor Receptor
8%
Endometrium Cancer
8%
Castration Resistant Prostate Cancer
8%
Disease Activity
8%
C Reactive Protein
8%
Fluorouracil
8%
Methotrexate
8%
Bleeding
8%
Crohn's Disease
8%
Heart Infarction
7%
Spinal Cord Injury
7%
Sepsis
7%
Recurrence Free Survival
7%
Docetaxel
7%
Breast Cancer
7%
Tocilizumab
7%
Vaccination Policy
7%
Clinical Feature
7%
Hospital Mortality
7%
Ovary Cancer
7%
Esophageal Squamous Cell Carcinoma
6%
Paclitaxel
6%
Normal Human
6%
Myasthenia gravis
6%
Angiotensin II
6%
Helicobacter Pylori
6%
Kidney Metastasis
6%
Clozapine
6%
Cross-Sectional Study
6%
Hearing Impairment
6%
Chronic Obstructive Lung Disease
6%
Side Effect
6%
Acute Heart Failure
5%
Ischemia
5%
Interleukin 6
5%
Clinical Study
5%
Lymph Node Metastasis
5%
Glucocorticoid
5%
Eye Disease
5%
Comorbidity
5%
Hemodialysis
5%
Vasculotropin
5%
Pharmacotherapy
5%
Inflammatory Bowel Disease
5%
Keyphrases
Japan
54%
Confidence Interval
24%
Overall Survival
14%
Clinical Outcomes
14%
Japanese Patients
14%
Tumor
13%
Hazard Ratio
12%
Risk Factors
12%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
12%
Rheumatoid Arthritis
12%
Esophageal Cancer
11%
Meta-analysis
10%
Odds Ratio
9%
Retrospective Cohort Study
8%
Ulcerative Colitis
8%
Clinical Practice Guidelines
8%
Dry Eye
8%
Endometrial Cancer
8%
COVID-19
8%
After Surgery
7%
Induced Pluripotent Stem Cells (iPSCs)
7%
Systematic Meta-analysis
7%
Spinal Cord Injury
7%
Graft-versus-host Disease (GvHD)
7%
Colorectal Cancer
6%
Hepatocellular Carcinoma
6%
Multicenter Cohort Study
6%
Chemotherapy
6%
Transplantation
6%
Adverse Events
6%
Surgical Outcomes
6%
Monotherapy
6%
Percutaneous Coronary Intervention
6%
Clinical Characteristics
6%
No Significant Difference
5%
Esophageal Squamous Cell Carcinoma
5%
Multivariate Analysis
5%
Recurrence-free Survival
5%
Neoadjuvant Chemotherapy
5%
Prognostic Factors
5%
Antipsychotics
5%
Postoperative Complications
5%
Randomized Controlled Trial
5%
Cisplatin
5%
Lung
5%
Progression-free Survival
5%
Upper Tract Urothelial Carcinoma
5%